Estrigenix Appoints Patricia Scheller as Executive Chairwoman

MILWAUKEE (Dec. 5, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is excited to announce Patricia Scheller as its executive chairwoman.   

In this role, Scheller will be actively involved in Estrigenix’s business. She will chair the board of directors, act as an advisor to William Donaldson, PhD, the company’s chief executive officer (CEO) and be involved in crafting the company’s business and financing strategies. 

“I feel very privileged to take on this role at such an exciting time for Estrigenix. Preliminary data indicates that the research Estrigenix is doing has the potential to positively and significantly impact the lives of millions of  women who suffer from hot flashes and memory dysfunction secondary to the onset of menopause.” said Scheller. “I look forward to working with the founders of Estrigenix to successfully guide the development process and secure appropriate business partners to commercialize the technology.”

Scheller previously served as CEO and director of Viveve (VIVE), a company she took public and built to a $125M market cap. Viveve was named one of Deloitte’s Fast Technology companies and was listed on the Russell Index during Scheller’s tenure.

Estrigenix’s novel compounds address the major side effects that occur following the dramatic decline in the production of estrogen during menopause: hot flashes, sleep disruption, memory dysfunction, anxiety, and depression. Although traditional hormone therapy (HT) addresses these symptoms, HT has associated risks for breast cancer and blood clots, leading to stroke. For this reason, many OB/GYNs will not prescribe HT for the approximately 20 percent of menopausal women with a history of breast or uterine cancer or stroke.

Recent clinical and preclinical findings demonstrate that the negative side effects of HT may be due to activation of the alpha, but not beta, estrogen receptor isoform. Therefore, estrogen-based HT that selectively targets ER beta may avoid the health risks associated with ER alpha activation.

Estrigenix developed highly selective ER beta agonists that, in pre-clinical testing, demonstrated long-term ER beta activation, reducing hot flash-like symptoms andenhancing spatial and object recognition memories in ovariectomized mice. These highly selective ER beta agonists have the potential to serve as a safe alternative to HT for more than sixty million menopausal women in the U.S. alone, 80 percent of whom experience symptoms including hot flashes and memory dysfunction. The severity and frequency of hot flashes are correlated with an increased risk for Alzheimer’s disease, which may help to explain why 2/3 of Alzheimer’s patients are women. Having a treatment that address hot flashes and memory dysfunction, but avoids the potential risks associated with traditional hormone therapy, such as cancer and stroke, would provide significant benefits for women.

To learn more about Estrigenix and how its technology may help improve women’s quality of life, visit


About Estrigenix Therapeutics, Inc.

Estrigenix Therapeutics, Inc. is a Wisconsin-based, privately held pharmaceutical company leading the way in research and progress in estrogen biology. Estrigenix was formed in 2018 to develop and commercialize first-in-class therapeutics to treat and prevent symptoms of menopause, including hot flashes and dementia, with fewer side effects than current hormone therapies. 

For more information and to learn how Estrigenix is pioneering the way in symptom prevention for menopausal women, visit

Safe Harbor Statement

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, implied and express statements regarding Estrigenix Therapeutics, Inc. plans, timelines, or presumptions of results for the Company’s lead compounds or planned development and testing. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on several assumptions concerning future events and are subject to several risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the timing, progress and results of our development efforts, the fluctuation of global economic conditions, the impact of current or future pandemics on our clinical development and regulatory review and approvals and on the manufacturing and prescribing of our lead compound, the performance of management and our employees, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our products for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Estrigenix Therapeutics is a registered trademark of Estrigenix Therapeutics, Inc.